At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
AIN457 +1 moredrug
Likely dose
AIN457 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
In Brief
A Phase 2 clinical trial evaluating AIN457 for Multiple Sclerosis. Completed, enrolled 39 participants across 14 sites in 3 countries.
Detailed Summary
The study will assess the long-term safety and tolerability of AIN457 in patients with relapsing-remitting multiple sclerosis (RRMS). In addition the long-term pattern of maintenance of efficacy and health related quality of life will be explored.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesCzechia, Russia, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartFeb 2012
Primary CompletionJun 2014
TodayJul 2026
First PostedSep 13, 2011
Enrollment StartFeb 1, 2012
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.8 years ago
Interventions
AIN457drug
(10mg/kg i.v.).
AIN457drug
(10mg/kg i.v.).